The Market for Compounded Veterinary Drugs Is Growing. Here’s Why That Matters for Your Practice.

A new market analysis suggests the global animal drug compounding market could grow from approximately $1.5 billion in 2026 to $2.3 billion by 2033, reflecting a compound annual growth rate of around 6–7 percent. Other firms report slightly different figures. For example, Grand View Research estimated the market at $1.52 billion in 2024 with a projected CAGR closer to 8 percent.

The exact numbers vary depending on how the market is defined. The directional story does not: steady, meaningful growth driven by real clinical demand.

Understanding why that growth is happening is more useful than the headline number.

What Is Actually Driving Demand

The core drivers are clinical, not marketing-driven. Compounded medications exist because commercially available, FDA-approved drugs cannot meet every patient’s needs.

Those gaps are practical and familiar to any veterinarian:

• A species or breed without an appropriately dosed formulation

• A cat that will not take a pill but accepts a transdermal gel

• A horse requiring a concentration not commercially available

• A patient with a documented sensitivity to an inactive ingredient

These are not edge cases. They are daily realities.

Across multiple analyses, central nervous system (CNS) agents — including anticonvulsants, anxiolytics, sedatives, and antidepressants — represent one of the largest segments of the compounding market. This aligns with clinical practice: neurological and behavioral conditions often require flexible dosing and alternative delivery methods, particularly in feline patients.

Anti-infective agents are frequently cited as one of the fastest-growing segments, driven by the need for customized antimicrobial formulations — adjusted concentrations, combination therapies, and alternative delivery routes tailored to specific infections or species.

The most important long-term driver is the rise in chronic disease management. As pets live longer, conditions such as diabetes, hyperthyroidism, hypothyroidism, and osteoarthritis are increasingly common. These cases require long-term, consistent medication administration — and compliance becomes a limiting factor.

A cat requiring methimazole twice daily for years presents a very different challenge than a short antibiotic course. The availability of transdermal options has meaningfully improved compliance and outcomes in these patients.

The Regulatory Context Matters

The animal compounding space operates within a regulatory framework that has evolved significantly in recent years. In the United States, U.S. Food and Drug Administration Guidance for Industry #256, finalized in 2022, outlines the conditions under which veterinarians and pharmacists may compound medications from bulk drug substances for animal patients.

This includes criteria for enforcement discretion and guidance around the use of outsourcing facilities.

Importantly, this framework is not a barrier to growth — it is a quality signal. Greater clarity has helped distinguish compliant, well-regulated compounding pharmacies from those operating outside appropriate standards. As a result, veterinary confidence in compounding has increased alongside regulatory consistency.

Geography of Demand

North America accounts for roughly 40–42 percent of the global market, driven by high pet ownership, a well-established network of compounding pharmacies, and a relatively mature regulatory environment. The United States represents the majority of that share.

Asia-Pacific is consistently identified as the fastest-growing region, fueled by increasing urbanization, rising pet ownership, and expanding veterinary infrastructure across countries such as China, India, Japan, and Australia. Growth rates are higher in these regions, though from a smaller base.

What This Means for Veterinary Practice

The data reflects what many practitioners already know: compounding is not a niche workaround — it is a standard component of modern veterinary care.

Practices that maintain strong relationships with reputable, compliant compounding pharmacies are better positioned to:

• Manage complex or chronic cases

• Improve medication compliance

• Deliver outcomes that standard formulations alone cannot support

As the market grows, competition among compounding providers is increasing. This typically leads to improvements in turnaround time, formulation options, and service quality. For practices that have not recently evaluated their compounding partners, the current landscape may offer better options than were available even a few years ago.

The demand is not being created by the market. It is coming from patients.

The market is simply catching up.

Data note: Market size projections in the animal drug compounding sector vary across research firms due to differences in scope, methodology, and base year. Figures cited from sources such as Grand View Research and others should be interpreted as directional estimates rather than precise valuations.